title: SERPINE1 Gene
SERPINE1 Gene
Overview
Mermaid diagram (expand to render)
SERPINE1 encodes plasminogen activator inhibitor-1 (PAI-1), the primary physiological inhibitor of tissue-type plasminogen activator (tPA) and urokinase-type plasminogen activator (uPA). As a member of the serpin superfamily, PAI-1 plays crucial roles in fibrinolysis regulation, extracellular matrix remodeling, and cellular signaling. Beyond its well-established functions in hemostasis and cardiovascular disease, PAI-1 has emerged as a significant contributor to neurodegenerative processes in Alzheimer's disease (AD), Parkinson's disease (PD), amyotrophic lateral sclerosis (ALS), and vascular cognitive impairment. The protein's roles in neuroinflammation, synaptic plasticity, blood-brain barrier (BBB) integrity, and protein aggregation position it as both a biomarker and therapeutic target in neurodegeneration. [@teesalu2013]
<div class="infobox infobox-gene">
| Property | Value |
|----------|-------|
| Gene Symbol | SERPINE1 |
| Gene Name | Serpin Family E Member 1 (PAI-1) |
| Chromosomal Location | 7q22.1 |
| NCBI Gene ID | [5054](https://www.ncbi.nlm.nih.gov/gene/5054) |
| OMIM | [173360](https://www.omim.org/entry/173360) |
| UniProt | [P05121](https://www.uniprot.org/uniprot/P05121) |
| Ensembl | [ENSG00000105341](https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000105341) |
| RefSeq mRNA | NM_000321 |
| Protein Length | 402 amino acids |
</div>
Protein Structure and Function
Plasminogen activator inhibitor-1 is a 46 kDa glycoprotein that exists in three conformational states: active, latent, and cleaved. The active form rapidly forms covalent complexes with tPA and uPA, while the latent form represents an inactive conformation that can be converted to active by various stimuli. [@teesalu2013]
Canonical Functions
Fibrinolysis Regulation: PAI-1 inhibits tPA and uPA, limiting plasmin generation and preventing excessive fibrinolysis. This balance is critical for hemostatic equilibrium.
Extracellular Matrix Remodeling: Through modulation of the plasminogen activator system, PAI-1 influences matrix metalloproteinase (MMP) activity and tissue remodeling processes.
Cellular Signaling: PAI-1 binds to the vitronectin receptor (integrin αvβ3), promoting cell adhesion and migration. This affects angiogenesis, wound healing, and cell survival.
Senescence Regulation: PAI-1 is a downstream effector of p53-induced senescence, positioning it as a key mediator of cellular aging processes.Brain-Specific Functions
Within the central nervous system, PAI-1 demonstrates additional functions:
- Synaptic Plasticity: PAI-1 modulates NMDA receptor signaling and affects long-term potentiation (LTP), with implications for memory formation. [@brown2021]
- Neuroinflammation: Astrocyte and microglial PAI-1 production influences cytokine expression and immune cell trafficking
- BBB Integrity: PAI-1 regulates pericyte function and endothelial-pericyte communication at the BBB. [@chen2022]
- Neural Stem Cell Biology: The protein affects neurogenesis and neural progenitor cell migration
Expression in the Brain
SERPINE1 is expressed in neurons, astrocytes, microglia, and endothelial cells within the brain. Basal expression is low but increases dramatically in response to inflammatory cytokines, oxidative stress, and aging. Cerebrospinal fluid PAI-1 levels are approximately 1/50th of plasma, though this ratio changes with neuroinflammation. The protein can cross the BBB in both directions under inflammatory conditions, establishing a connection between peripheral and CNS PAI-1 dynamics.
Disease Associations
Alzheimer's Disease
PAI-1 demonstrates multiple relationships with AD pathogenesis:
- Amyloid Metabolism: PAI-1 regulates tPA-mediated plasmin generation, which degrades amyloid-beta (Aβ) peptides. Elevated PAI-1 in AD brains reduces fibrinolysis and Aβ clearance. [@faut2022]
- Tau Pathology: PAI-1 expression correlates with hyperphosphorylated tau levels. The protein promotes tau aggregation and propagation through effects on extracellular proteolysis. [@schwab2020]
- Neuroinflammation: PAI-1 amplifies microglial activation and cytokine release. This creates a feed-forward loop where inflammation increases PAI-1, which further promotes inflammation.
- Vascular Contributions: Given the vascular components of AD pathology, PAI-1's role in fibrin deposition and small vessel disease is highly relevant.
- Genetic Associations: SERPINE1 polymorphisms influence AD risk and age of onset in multiple cohort studies. The 4G/5G promoter polymorphism shows variable associations.
Parkinson's Disease
In PD, PAI-1 exhibits complex relationships with alpha-synuclein pathology:
- Alpha-Synuclein Aggregation: PAI-1 interacts with alpha-synuclein and influences its aggregation kinetics. The protein may promote oligomer formation while inhibiting fibrilization.
- Dopaminergic Neuron Vulnerability: PAI-1 is elevated in the substantia nigra of PD patients, where it may contribute to dopaminergic neuron death through effects on neuroinflammation and blood-brain barrier function. [@tang2019]
- Microglial Activation: The protein promotes microglial activation and migration, potentially exacerbating neuroinflammation in PD.
- Oxidative Stress: PAI-1 expression is induced by oxidative stress, creating a pathogenic cycle in PD pathogenesis.
- Clinical Correlations: CSF PAI-1 levels correlate with disease severity and motor symptom progression in PD patients.
Amyotrophic Lateral Sclerosis
SERPINE1 plays significant roles in ALS pathophysiology:
- Motor Neuron Vulnerability: PAI-1 is elevated in ALS spinal cord and CSF, correlating with disease progression. The protein promotes neuroinflammation and microglial activation. [@hansen2021]
- Extracellular Matrix: ALS involves significant extracellular matrix remodeling, in which PAI-1 plays a key role through effects on plasmin generation and MMP activity.
- Vascular Components: Given the vascular contributions to ALS pathogenesis, PAI-1's role in blood-spinal cord barrier dysfunction is relevant.
- Genetic Modifiers: SERPINE1 polymorphisms influence ALS survival and age of onset in large GWAS studies.
Vascular Cognitive Impairment
PAI-1 is particularly relevant to vascular contributions to cognitive decline:
- Small Vessel Disease: PAI-1 promotes fibrin deposition in cerebral small vessels, contributing to vascular cognitive impairment. [@liu2020]
- White Matter Damage: The protein affects white matter integrity through effects on perfusion and blood-brain barrier function.
- Post-Stroke Recovery: Elevated PAI-1 impairs functional recovery after stroke through effects on plasticity and inflammation.
Other Neurodegenerative Conditions
- Frontotemporal Dementia: PAI-1 elevations in specific subtypes, particularly those with prominent neuroinflammation
- Huntington's Disease: Elevated PAI-1 in striatum, correlating with disease progression
- Multiple Sclerosis: PAI-1 in demyelinating lesions; affects remyelination efficiency
Mechanism of Action in Neurodegeneration
Neuroinflammation Amplification
PAI-1 promotes neuroinflammation through multiple mechanisms:
Cytokine Production: PAI-1 increases TNF-α, IL-1β, and IL-6 production from activated microglia
Inflammasome Activation: The protein promotes NLRP3 inflammasome activation through undefined mechanisms
Immune Cell Recruitment: PAI-1 affects chemokine production and leukocyte trafficking
Astrocyte Reactivity: PAI-1 modulates astrocyte activation and reactive gliosisBlood-Brain Barrier Dysfunction
PAI-1 contributes to BBB breakdown:
- Pericyte Function: PAI-1 affects pericyte survival and contractility
- Endothelial Junction Integrity: The protein influences tight junction protein expression
- Matrix Deposition: PAI-1 promotes basement membrane accumulation
Synaptic Dysfunction
PAI-1 affects synaptic plasticity:
- NMDA Receptor Modulation: PAI-1 influences NMDA receptor trafficking and signaling
- LTP Impairment: Elevated PAI-1 correlates with impaired long-term potentiation
- Dendritic Spine Changes: The protein affects spine density and morphology
Protein Aggregation
PAI-1 interacts with aggregation-prone proteins:
- Amyloid-Beta: Modulates aggregation kinetics and toxicity
- Tau: Promotes hyperphosphorylation and aggregation
- Alpha-Synuclein: Influences oligomer formation
Genetic Variants
| Variant | Location | Effect | Clinical Relevance |
|---------|----------|--------|-------------------|
| 4G/5G | Promoter (-675) | Altered expression | Cardiovascular disease, possibly AD |
| 1100T>C (Vallle) | Exon 9 | Altered activity | Thrombosis risk |
| 3103G>A | 3'UTR | mRNA stability | May affect expression |
The 4G/5G promoter polymorphism has been extensively studied in neurodegeneration, with inconsistent results across populations and diseases.
Therapeutic Implications
PAI-1 Inhibitors
Several PAI-1 inhibitors are in development:
- Small Molecule Inhibitors: TM5441 and related compounds已进入临床前评估
- Natural Products: Various flavonoids and polyphenols show PAI-1 inhibitory activity
- Neutralizing Antibodies: Monoclonal antibodies against PAI-1 are under development
Repurposing Opportunities
Existing drugs with PAI-1 modulatory effects:
- Statins: Some statins reduce PAI-1 expression
- ACE Inhibitors: Show PAI-1 reducing effects
- Thiazolidinediones: PPARγ agonists decrease PAI-1 levels
Mechanism-Based Approaches
- tPA Enhancement: Agents that increase tPA activity can overcome PAI-1 inhibition
- Fibrinolytic Therapy: Recombinant tPA administration in appropriate contexts
- Gene Therapy: Viral vector-mediated PAI-1 knockdown approaches
Biomarker Potential
PAI-1 possesses significant biomarker utility:
- CSF PAI-1: Elevated in AD, PD, ALS; correlates with disease severity
- Blood PAI-1: Systemic inflammation marker; less CNS-specific
- Combined Biomarkers: PAI-1 with tPA ratio shows diagnostic promise
Research Directions
Key areas for future investigation:
- PAI-1 therapeutic targeting in human neurodegeneration trials
- Mechanism of PAI-1 effects on synaptic plasticity
- BBB penetration by PAI-1 modulators
- Genetic stratification based on SERPINE1 variants
- Combination therapy with existing treatments
References
[Kawamoto et al., PAI-1 in neurodegeneration (2020)](https://doi.org/10.1016/j.neurobiolaging.2020.03.012)
[Erickson et al., SERPINE1 and aging (2019)](https://doi.org/10.1093/gerona/glz137)
[Teesalu et al., PAI-1 function and pathology (2013)](https://doi.org/10.1016/j.tcb.2013.04.004)
[Faut et al., PAI-1 and Alzheimer's disease pathology (2022)](https://doi.org/10.1038/s41598-022-16789-8)
[Tang et al., SERPINE1 in Parkinson's disease (2019)](https://doi.org/10.1002/mds.27789)
[Schwab et al., PAI-1 and tau pathology (2020)](https://doi.org/10.1093/brain/awaa123)
[Hansen et al., PAI-1 in ALS pathogenesis (2021)](https://doi.org/10.1093/jnen/nlab028)
[Jacobsen et al., SERPINE1 polymorphisms and neurodegeneration (2020)](https://doi.org/10.1016/j.neurobiolaging.2020.06.015)
[Zhang et al., PAI-1 and neuroinflammation (2021)](https://doi.org/10.1038/s41419-021-03767-7)
[Chen et al., PAI-1 and blood-brain barrier (2022)](https://doi.org/10.1161/STROKEAHA.121.038367)
[Liu et al., PAI-1 in vascular cognitive impairment (2020)](https://doi.org/10.1111/jcmm.15987)
[Brown et al., SERPINE1 and synaptic plasticity (2021)](https://doi.org/10.1016/j.neuropharm.2021.108422)
[Miller et al., PAI-1 inhibitors as neuroprotective agents (2022)](https://doi.org/10.1016/j.tips.2022.03.005)See Also
- [Plasminogen Activator System](/mechanisms/plasminogen-activator-system)
- [Alzheimer's Disease](/diseases/alzheimers-disease)
- [Parkinson's Disease](/diseases/parkinsons-disease)
- [Amyotrophic Lateral Sclerosis](/diseases/amyotrophic-lateral-sclerosis)
- [Vascular Cognitive Impairment](/diseases/vascular-cognitive-impairment)
- [Neuroinflammation Mechanisms](/mechanisms/neuroinflammation-mechanisms)
- [Blood-Brain Barrier in Neurodegeneration](/mechanisms/blood-brain-barrier-neurodegeneration)
- [Synaptic Dysfunction Mechanisms](/mechanisms/synaptic-dysfunction-mechanisms)
- [NCBI Gene](https://www.ncbi.nlm.nih.gov/gene/5054)
- [OMIM](https://www.omim.org/entry/173360)
- [UniProt](https://www.uniprot.org/uniprot/P05121)
- [Ensembl](https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000105341)
Pathway Diagram
The following diagram shows the key molecular relationships involving SERPINE1 Gene discovered through SciDEX knowledge graph analysis:
Mermaid diagram (expand to render)